Were studied endothelioprotective and antiaggregant properties of Primula veris L. solid herbal extract (PVSHE) in animals under experimental chronic heart failure (CHF) caused by isoproterenol administration in a dose of 2,5 mg / kg twice a day for 21 days. It was shown that in the control group of animals with CHF, the introduction of acetylcholine increased by 21,2 %, while the non-selective NO-synthase inhibitor L-NAME reduced the rate of blood flow in the carotid artery of rats by 27,5 %, which was less than the same values in the intact group: 45,2 % and -46,8 %, respectively (p < 0,05). The introduction of acetylcholine caused an increase in the rate of blood flow in the carotid artery in rats with CHF who received PVSHE at a dose of 30 mg / kg by 43,4 % and mildronate at a dose of 50 mg / kg - by 43,8 %, which was significantly higher than in animals of the control group (p < 0,05). The non-selective inhibitor of NO-synthase L-NAME reduced blood flow in the animals with CHF receiving study medications: -40,4 % and -39,5 % (p < 0,05), respectively It was found that the rate and degree of aggregation of platelets was higher in rats with CHF than in intact animals (29,6 % / min versus 20,6 % / min and 27,3 % vs. 18,8 %, p < 0,05, respectively ). In rats with CHF receiving PVSHE, the rate of blood flow in the carotid artery was 20% / min, mildronate -23,2 % / min, the degree of aggregation was 19 % and 21,9 %, respectively which was significantly lower in comparison with animals of the control group (p < 0,05). It was found that the level of von Willebrand factor (vW) was higher in animals with CHF than in the intact group by 91,1 % (p < 0.05) and significantly lower in animals with CHF who received PVSHE by 31,4 % (p < 0,05) and mildronate 21,2 % relative to the control group of rats (p < 0,05). The obtained data testify to the endothelioprotective and antiaggregant effect of the PVSHE comparable to the comparative preparation mildronate.
Read full abstract